Petros Pharmaceuticals, Inc. Profile

Drug Manufacturers—Specialty & Generic
Number of Employees

Petros Pharmaceuticals's Business Model

Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease. The company markets its line of ED products in the form of vacuum erection device products. Petros Pharmaceuticals, Inc. is based in New York, New York.

About Petros Pharmaceuticals


CEO (Chief Executive Officer): Mr. John David Shulman

IPO date: 2020-12-02


Country: US

Address: 1185 Avenue of the Americas

City: New York

State: NY

Phone: 973-242-0005

Zip Code: 10036


CIK: 0001815903

ISIN: CNE100004QC9

CUSIP: 71678J100

Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.